Stereoselective disposition of S- and R-Licarbazepine in mice

Chirality

Volumn 20, Issue 6, 2008, Pages 796-804

  Alves, Gilberto ^a   Figueiredo, Isabel ^a   Falcão, Amílcar ^a   Castel Branco, Margarida ^a   Caramona, Margarida ^a   Soares Da Silva, Patrício ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

Chiral separation; Eslicarbazepine acetate; Licarbazepine enantiomers; Mouse plasma and tissues; Oxcarbazepine; Pharmacokinetics; Stereoselectivity

Indexed keywords

10 ACETOXY 10,11 DIHYDRO 5H DIBENZ[B,F]AZEPINE 5 CARBOXAMIDE; BIA 2 195; BIA 2 265; DRUG METABOLITE; LICARBAZEPINE; 10,11 DIHYDRO 10 HYDROXY 5H DIBENZ(B,F)AZEPINE 5 CARBOXAMIDE; 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIBENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; OXCARBAZEPINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BLOOD FLOW VELOCITY; CHIRALITY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEREOCHEMISTRY; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS; ANIMAL; BIOLOGICAL MODEL; BLOOD; BRAIN; CHEMISTRY; KIDNEY; LIVER; METABOLISM; METHODOLOGY; STEREOISOMERISM; TISSUE DISTRIBUTION;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIBENZAZEPINES; KIDNEY; LIVER; MALE; MICE; MODELS, BIOLOGICAL; STEREOISOMERISM; TISSUE DISTRIBUTION;

EID: 45849105592     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20546     Document Type: Article

References (29)

1. Andersson T. Single-isomer drugs: true therapeutic advances. Clin Pharmacokinet 2004;43:279-285.
2. Kan AY, Preskorn SH, Wimalasena K. Single enantiomer drugs: should they be developed? Essent Psychopharmacol 2006;7:15-23.
3. Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 1996;52 (Suppl 5):1-12.
4. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753-768.
5. Hutt AJ. The development of single-isomer molecules: why and how. CNS Spectr 2002;7 (Suppl l):14-22.
6. Agrawal YK, Bhatt HG, Raval HG, Oza PM, Gogoi PJ. Chirality - a new era of therapeutics. Mini Rev Med Chem 2007;7:451-460.
7. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497-504.
8. Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, Cunha RA, Garrett J, Soares-da-Silva P. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f] azepine-5carboxamide derivatives. J Med Chem 1999;42:2582-2587.
9. Hainzl D, Parada A, Soares-da-Silva P. Metabolism of two new antiepi-leptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihy-dro-10-hydroxy carbamazepine. Epilepsy Res 2001;44:197-206.
10. Matar KM, Nicholls PJ, Bawazir SA, Al-Hassan MI, Tekle A. Effect of valproic acid on the pharmacokinetic profile of oxcarbazepine in the rat Pharm Acta Helv 1999;73:247-250.
11. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006;15:637-647.
12. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003;42:1023-1042.
13. Flesch G, Francotte E, Hell F, Degen PH. Determination of the R-(-) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. J Chromatogr 1992;581:147-151.
14. Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999;66:547-553.
15. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 2004;24:185-203.
16. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007;73:1-52.
17. Almeida L, Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R D 2003;4:269-284.
18. Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004;44:906-918.
19. Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005;45:1062-1066.
20. Volosov A, Yagen B, Bialer M. Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. Epilepsia 2000;41:1107-1111.
21. Alves G, Figueiredo I, Castel-Branco M, Loureiro A, Falcão A, Cara-mona M. Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R- licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. Anal Chim Acta 2007;596:132-140.
22. Levy RH, Boddy AV. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991;8:551-556.
23. Caldwell J. Importance of stereospecific bioanalytical monitoring in drug development J Chomatogr A 1996;719:3-13.
24. Rentsch KM. The importance of stereoselective determination of drugs in clinical laboratory. J Biochem Biophys Methods 2002;54:1-9.
25. Wsó1 V, Skálová L, Szotáková B. Chiral inversion of drugs: coincidence or principle? Curr Drug Metab 2004;5:517-533.
26. p,uu. Drug Metab Dispos 2006;34:318-323.
27. Doan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. Passive permeability and Pglycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002;303:1029-1037.
28. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 2005;314:725-731.
29. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61:1-48.